|

Scientific Program

wed06jul08:0009:30Registration08:00 - 09:30


wed06jul09:3009:45Presidents' Welcome SpeechPhaedon Kaklamanis, Petros Sfikakis09:30 - 09:45


wed06jul09:4510:30Opening Lecture | Chairs: P. Kaklamanis, P. SfikakisImmune Cell Signaling, Gene Transcription and Mechanisms of Tissue Injury
George Tsokos09:45 - 10:30


wed06jul10:3011:00Coffee and tea break10:30 - 11:00


wed06jul11:0013:00SESSION 1 - Basic and Translational ScienceChairs: D. Haskard , J. van Laar11:00 - 13:00


wed06jul11:0011:25Immunology, inflammation and thrombosisGiacomo Emmi11:00 - 11:25


wed06jul11:2511:50Immunopathogenesis of Behçet's diseaseAhmet Gül11:25 - 11:50


wed06jul11:5012:15Behçet’s disease and microbesGraham Wallace11:50 - 12:15


wed06jul12:1512:40Immune Senescence in Behçet’s diseaseEun-So Lee12:15 - 12:40


wed06jul12:4012:50Oral Presentation (O01) | Proteomic landscape mapping of organ-resolved Behçet’s disease using in-depth plasma proteomics for identifying HABP2 expression associated with vascular damageLinlin Cheng12:40 - 12:50


wed06jul12:5013:00Oral Presentation (O02) | Single-cell analyses highlight the proinflammatory contribution of C1q-high monocytes to Behçet’s diseaseWenjie Zheng12:50 - 13:00


wed06jul13:0013:30Lunch Break13:00 - 13:30


wed06jul13:3014:00Special Lecture | Chair: A. GaryfallosThe expanding role of apremilast in the treatment of Behcet’s syndrome
Yusuf Yazici13:30 - 14:00


wed06jul14:0014:30Satellite Lecture sponsored by ABBVIE | Chair: G. KitasUnravelling the management of Non-Infectious Uveitis
Dimitrios Ladas14:00 - 14:30


wed06jul14:3015:30Poster Tour 1 - Basic Science, Genetics and EpidemiologyChairs: V. Kaklamani, A. Fanouriakis14:30 - 15:30


wed06jul15:3017:30SESSION 2 - Difficult to Treat Behçet's DiseaseChairs: I. Koné-Paut, N. Markomichelakis, H. Direskeneli15:30 - 17:30


wed06jul15:3016:10Ocular Behçet’sCase Presentation (5’) Dimitrios Ladas
Case Discussion and review (20’) Ilknur Tugal-Tutkun
External comments (8’) Lothar Krause
Discussion (7’) - Audience15:30 - 16:10


wed06jul16:1016:50Vascular Behçet’sCase Presentation (5’) Adrien Mirouse
Case Discussion and review (20’)David Saadoun
External comments (8’) Emire Seyahi
Discussion (7’) - Audience16:10 - 16:50


wed06jul16:5017:30Juvenile Behçet’sCase Presentation (5’) Lampros Fotis
Case Discussion and review (20’) Paul Brogan
External comments (8’) Aristeidis Vaiopoulos
Discussion (7’) - Audience16:50 - 17:30


wed06jul17:3018:15Special Lecture | Chair: H. YaziciReproducible and useful research on risk factors and treatments
John Ioannidis17:30 - 18:15


wed06jul20:00Official Welcome ReceptionNational & Kapodistrian University of Athens History Museum 5, Tholou street Plaka, Acropolis of Athens20:00

*Please note that all times are Local Greece times (UTC/GMT +3 hours)

thu07jul08:3010:30SESSION 3 - Genetics and Epidemiology : Is it all in the genes?Chairs: G. Wallace, A. Mahr08:30 - 10:30


thu07jul08:3008:50Shared genetic findings between canker sores, PFAPA and Behçet’s diseaseKalpana Manthiram08:30 - 08:50


thu07jul08:5009:10Behçet’s disease and primary immunodeficiencies: differences and similarities?Petrus Martin Van Hagen08:50 - 09:10


thu07jul09:1009:30Epidemiology of Behçet’s diseaseAndreas Altenburg09:10 - 09:30


thu07jul09:3009:50Differential clinical presentation of Behçet’s disease in non- endemic and endemic areasLuca Cantarini09:30 - 09:50


thu07jul09:5010:10HLA-B51 and ERAP in Behçet’s diseaseFarhad Shahram09:50 - 10:10


thu07jul10:1010:20Oral Presentation (O03) | A genetically and immunologically discernable BD endotype entails HLA class I- restricted oligoclonal CD8 effector T cell expansionsJohannes Nowatzky10:10 - 10:20


thu07jul10:2010:30Oral Presentation (O04) | Sex-specific analysis in Behçet’s disease reveals higher genetic risk in male patientsAmr Sawalha10:20 - 10:30


thu07jul10:3010:50Coffee and tea break10:30 - 10:50


thu07jul10:5012:10SESSION 4 - Difficult to Treat Behçet's DiseaseChairs: M. Schirmer, Α. Stratigos10:50 - 12:10


thu07jul10:5011:30Neuro- Behçet’sCase Presentation (5’) Dimitrios Papadopoulos
Case Discussion and review (20’) Aksel Siva
External comments (8’) Ugur Uygunoglu
Discussion (7’) - Audience10:50 - 11:30


thu07jul11:3012:10Mucocutaneous Behçet’sCase Presentation (5’) Cansu Burcin Bozca
Case Discussion and review (20’) Erkan Alpsoy
External comments (8’)Sara Trevisini
Discussion (7’) - Audience11:30 - 12:10


thu07jul12:1013:00SESSION 5 - Challenges in DiagnosisChairs: M. Tektonidou, G. Vaiopoulos12:10 - 13:00


thu07jul12:1012:35What is not Behçet disease?Hasan Yazici12:10 - 12:35


thu07jul12:3513:00Recent advances for the diagnosis in Behçet diseaseHaner Direskeneli12:35 - 13:00


thu07jul13:0014:30Satellite Symposium & Lunch Sponsored by NOVARTISChair: P. Sfikakis13:00 - 14:30


thu07jul13:0013:30Autoinflammation today: An ubiquitous pathogenetic mechanismJeroen Van der Hilst13:00 - 13:30


thu07jul13:3014:00FMF and Behcet disease: more than just an association?Ahmet Gül13:30 - 14:00


thu07jul14:0014:30IL-1β inhibition in FMF: clinical outcomes and expectationsEldad Ben Chetrit14:00 - 14:30


thu07jul14:3015:30Poster Tour 2 – Clinical AspectsChairs: M. Manoussakis, T. Taktak14:30 - 15:30


thu07jul15:3017:20SESSION 6 - Treatment - WIN (what is new)Chairs: D. Boumpas, P.M. Van Hagen15:30 - 17:20


thu07jul15:3016:00Year in Review – WINVedat Hamuryudan15:30 - 16:00


thu07jul16:0016:30Biologics and small molecules beyond anti-TNFYusuf Yazici16:00 - 16:30


thu07jul16:3016:50Adamantiades - Behçet's disease in the context of the European Reference Networks for Rare Diseases - A chance for Harmonization of Old Effective and New TreatmentsChristos C. Zouboulis16:30 - 16:50


thu07jul16:5017:00Development of Japanese Guidelines for the Treatment of Ocular Behçet's DiseaseMasaki Takeuchi16:50 - 17:00


thu07jul17:0017:10Oral Presentation (O05) | A therapy strategy to combat immunosenescence of Behçet’s diseaseHeera Lee17:00 - 17:10


thu07jul17:1017:20Oral Presentation (O06) | BioBehçet’s: Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab vs alpha interferon, with genotyping and metabolomic profiling, towards a stratified medicines approach to treatmentRobert Moots17:10 - 17:20


thu07jul17:2017:30Coffee Break17:20 - 17:30


thu07jul17:3018:30GENERAL ASSEMBLY17:30 - 18:30

*Please note that all times are Local Greece times (UTC/GMT +3 hours)

fri08jul08:0009:00Poster Tour 3 - Outcome Measures and Treatment AspectsChairs: K. Laskari, E. Seyahi08:00 - 09:00


fri08jul09:0009:30Coffee Break09:00 - 09:30


fri08jul09:3010:15Keynote Lecture | Chairs: A. Tzioufas, D. VassilopoulosThe journey of TNF blockade
George Kollias09:30 - 10:15


fri08jul10:1512:15SPECIAL SESSION - Towards A Treat-To-Target StrategyChairs: A. Gül, G. Fragoulis, P. Sfikakis10:15 - 12:15


fri08jul10:1510:35Treat to target in pleomorphic diseases – the lupus paradigmGeorge Bertsias10:15 - 10:35


fri08jul10:3510:55Measuring Behçet's disease activityGonca Mumcu10:35 - 10:55


fri08jul10:5511:15OMERACT - standardization of outcome measuresGülen Hatemi10:55 - 11:15


fri08jul11:1511:35Therapeutic targets in Behçet's diseaseJan van Laar11:15 - 11:35


fri08jul11:3511:55Targeting remission in ocular manifestations in Behçet's diseaseBahram Bodaghi11:35 - 11:55


fri08jul11:5512:15Implementing treat to target in treatment recommendations and discussionPetros Sfikakis & Audience11:55 - 12:15


fri08jul12:1512:30Closing remarksDorian Haskard, Michael Schirmer, Petros Sfikakis12:15 - 12:30


fri08jul13:0018:00Virtual Program13:00 - 18:00


fri08jul13:0014:40SESSION 1 Treatment AspectsChairs: J. Sota, K. Chatzidionysiou, P. Theodosiadis13:00 - 14:40


fri08jul13:0013:40Difficult to treat Behçet's Disease: Gastrointestinal Behçet’sCase Presentation (5’) Yohei Kirino
Case Discussion and review (20’) Jae Hee Cheon
External comments (8’)Mitsuhiro Takeno
Discussion (7’) - Audience13:00 - 13:40


fri08jul13:4014:20Non-infectious uveitis: advances in treatment13:40 - 14:20


fri08jul13:4013:55TNF inhibitorsRola N. Hamam13:40 - 13:55


fri08jul13:5514:05IL-1 inhibitorsKaterina Laskari13:55 - 14:05


fri08jul14:0514:20IL-6, IL-23, IL-17 and JAK inhibitorsClaudia Fabiani14:05 - 14:20


fri08jul14:2014:40Adherence to treatment in Behçet’s disease: a multifaceted issueRosaria Talarico14:20 - 14:40


fri08jul14:4015:05Special Lecture 1 | Chair: P. TrontzasThe management of ANCA systemic vasculitis: What has changed in the last 10 years
Dimitrios Vassilopoulos14:40 - 15:05


fri08jul15:0516:05SESSION 2 Pathogenetic AspectsChairs: C. Mavragani, S. Ugurlu15:05 - 16:05


fri08jul15:0515:25Biomarkers in Behçet’s diseaseKamel Hamzaoui15:05 - 15:25


fri08jul15:2515:45Current aspects of molecular background and treatment of ocular Behçet’s diseaseQuan Dong Nguyen15:25 - 15:45


fri08jul15:4516:05Omics in Behçet’s diseaseNikolaos Vlachogiannis15:45 - 16:05


fri08jul16:0516:25Special Lecture 2 | Chair: G. FragoulisBibliometric and altmetric analysis of publications in the field of Behçet’s disease
Armen Gasparyan & Olena Zimba16:05 - 16:25


fri08jul16:2516:45SESSION 3 Clinical AspectsChairs: P. Murray, L. Serpa Pinto, E. Silvestri16:25 - 16:45


fri08jul16:2516:45Covid-19 in patients with Behçet’s diseaseFarida Fortune16:25 - 16:45


fri08jul16:4517:05Behçet’s disease and pregnancyEldad Ben Chetrit16:45 - 17:05


fri08jul17:0517:25Cardiac involvement in Behçet’s diseaseSamar Tharwat17:05 - 17:25


fri08jul17:2517:45Behçet’s disease in IranSeyedeh Tahereh Faezi17:25 - 17:45


fri08jul17:4518:00Special Lecture 3 | Chair: D. HaskardColorful history of the International Conferences on Behçet’s disease from Rome to Athens
Nihat Dilsen17:45 - 18:00

*Please note that all times are Local Greece times (UTC/GMT +3 hours)

X